Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Kirurgi-indusert traume etter total versus medial unicompartmental knearthroplasty (SITA) (SITA)

17. september 2026 oppdatert av: Anders Troelsen, Hvidovre University Hospital

Påvirker kirurgi-indusert traume postoperativ sikkerhet og utfall ved å sammenligne total vs. medial unicompartmental knearthroplasty (SITA): En prospektiv kohortstudie

Osteoarthritis (OA) is the most common type of arthritis, characterized by pain and physical disability. More than 10% of persons > 55 years have symptomatic OA, primarily involving the knees. Knee arthroplasty is considered a successful orthopaedic procedure in progressed knee OA (KOA) with severe pain and disability where non-surgical treatments have been tried.

It has long been recognized that injury to the body, either from trauma or surgery causes an inflammatory response. As TKA is considered a more invasive procedure compared with UKA, TKA and UKA may not trigger inflammatory reactions of the same magnitude. Differences in inflammatory response between TKA and UKA could help explain why differences in outcome are present, despite both procedures being technically successful.

Even though knee arthroplasty is a very common and successful procedure, there are no existing studies comparing the invasiveness of TKA and UKA. As morbidity and mortality rates differ between the groups, the aim of this prospective cohort study is to investigate whether the post-operative inflammatory responses differ between TKA and UKA, and secondarily whether this difference can explain the difference in outcome between the two procedures.

The investigators hypothesize that TKA generates a larger postoperative systemic inflammatory response compared with UKA due to more extensive periarticular soft tissue and bone trauma.

The study's primary outcome is C-reactive Protein (CRP) measured in blood 24 hours after surgery (22-26 hours after surgery ~ day 1).

Participants which are candidates for either a TKA or a UKA will through serial blood test measurement have their postoperative systemic inflammatory response measured. This further will be correlated to the clinical and functional outcomes over a 2-years postoperative follow-up period.

Studieoversikt

Studietype

Observasjonsmessig

Registrering (Faktiske)

29

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Hvidovre, Danmark, 2650
        • Department of Orthopaedic Surgery, Amager Hvidovre Hospital

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

Study participants will be adults (i.e. at least 18 years old) who have diagnosis of KOA with an indication for primary KA (medial unicondylar or total arthroplasty).

Beskrivelse

Inclusion Criteria:

  • Age 18 or more
  • A clinical and radiological diagnosis of knee OA
  • Candidate for spinal anaesthesia
  • signed informed consent

Exclusion Criteria:

  • Planned surgery within the observation period other than KA
  • Any contraindications to the use of torniquet during surgery
  • Any contraindication to the administration of pre-operative dexamethasone
  • KA indication due to sequelae of e.g. fracture(s)
  • Previous infection of the target knee joint
  • Injection of medication or substances in the target knee within 3 months prior to participation
  • Immuno-inflammatory arthritis as cause of knee OA
  • Known autoimmune and/or inflammatory disease e.g. colitis ulcerosa
  • Active cancer diagnosis with ongoing treatment
  • Current systemic treatment with glucocorticoids equivalent to > 7.5 mg prednisolone/day
  • Surgery requiring spinal/general anaesthesia within the last 3 months prior to inclusion
  • Infection requiring medical/surgical treatment within the last 4 weeks prior to surgery for KA
  • Neurological dysfunction compromising mobility
  • Inability to understand or read Danish incl. instructions and questionnaires
  • Any other condition or impairment that, in the opinion of the investigator (or his/her delegate), makes a potential participant unsuitable for participation or which obstruct participation.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Observasjonsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Kohorter og intervensjoner

Gruppe / Kohort
Intervensjon / Behandling
Total Knee Arhroplasty (TKA)

Study participants will be adults (i.e. at least 18 years old) who have diagnosis of KOA with an indication for primary Total Knee Arthroplasty (TKA).

The choice between TKA and UKA is based on the radiological presentation of the knee KOA on an x-ray. A surgery with TKA involves the replacement of both the medial and lateral compartments of the knee.

Unicompartmental Knee Arthroplasty (UKA)

Study participants will be adults (i.e. at least 18 years old) who have diagnosis of KOA with an indication for primary medial Unicompartmental Knee Arthroplasty (UKA).

The choice between TKA and UKA is based on the radiological presentation of the knee KOA on an x-ray. A surgery with UKA involves the replacement of one compartment.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
C-reactive protein (CRP)
Tidsramme: Day 1 (24 hours after surgery)

Marker of systemic inflammation and soft tissue injury

Day 1 (24 hours after surgery)

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Interleukin-1-beta (IL1-beta)
Tidsramme: Baseline, 2 hours, 1 day, 7 days, and 21 days (after surgery)

Marker of systemic inflammation and soft tissue injury

Baseline, 2 hours, 1 day, 7 days, and 21 days (after surgery)
Interleukin-6 (IL6)
Tidsramme: Baseline, 2 hours, 1 day, 7 days, and 21 days (after surgery)

Marker of systemic inflammation and soft tissue injury

Baseline, 2 hours, 1 day, 7 days, and 21 days (after surgery)
Interleukin-8 (IL8)
Tidsramme: Baseline, 2 hours, 1 day, 7 days, and 21 days (after surgery)

Marker of systemic inflammation and soft tissue injury

Baseline, 2 hours, 1 day, 7 days, and 21 days (after surgery)
Tumor necrosis factor alfa (TNF-alfa)
Tidsramme: Baseline, 2 hours, 1 day, 7 days, and 21 days (after surgery)

Marker of systemic inflammation and soft tissue injury

Baseline, 2 hours, 1 day, 7 days, and 21 days (after surgery)
Metalloproteinases (MMP3, MMP9, MMP13)
Tidsramme: Baseline, 2 hours, 1 day, 7 days, and 21 days (after surgery)

Marker of systemic inflammation and soft tissue injury

Baseline, 2 hours, 1 day, 7 days, and 21 days (after surgery)
Calprotectin - S100 calcium binding protein A8/A9 (S100A8/S100A9)
Tidsramme: Baseline, 2 hours, 1 day, 7 days, and 21 days (after surgery)

Marker of systemic inflammation and soft tissue injury

Baseline, 2 hours, 1 day, 7 days, and 21 days (after surgery)
S100 calcium-binding protein B (S100B)
Tidsramme: Baseline, 2 hours, 1 day, 7 days, and 21 days (after surgery)

Marker of systemic inflammation and soft tissue injury

Baseline, 2 hours, 1 day, 7 days, and 21 days (after surgery)
C-Reactive Protein (CRP)
Tidsramme: Baseline, 2 hours, 1 day, 7 days, and 21 days (after surgery)

Marker of systemic inflammation and soft tissue injury

Baseline, 2 hours, 1 day, 7 days, and 21 days (after surgery)
Haemoglobin (Hb)
Tidsramme: Baseline, 2 hours, 1 day, 7 days, and 21 days (after surgery)

Marker of systemic inflammation and soft tissue injury

Baseline, 2 hours, 1 day, 7 days, and 21 days (after surgery)
Erythrocyte Sedimentation Rate (ESR)
Tidsramme: Baseline, 2 hours, 1 day, 7 days, and 21 days (after surgery)

Marker of systemic inflammation and soft tissue injury

Baseline, 2 hours, 1 day, 7 days, and 21 days (after surgery)
White cell count (L+D)
Tidsramme: Baseline, 2 hours, 1 day, 7 days, and 21 days (after surgery)

Marker of systemic inflammation and soft tissue injury

Baseline, 2 hours, 1 day, 7 days, and 21 days (after surgery)
Platelets
Tidsramme: Baseline, 2 hours, 1 day, 7 days, and 21 days (after surgery)

Marker of systemic inflammation and soft tissue injury

Baseline, 2 hours, 1 day, 7 days, and 21 days (after surgery)
Myoglobin
Tidsramme: Baseline, 2 hours, 1 day, 7 days, and 21 days (after surgery)

Marker of systemic inflammation and soft tissue injury

Baseline, 2 hours, 1 day, 7 days, and 21 days (after surgery)
Lactate dehydrogenase (LDH)
Tidsramme: Baseline, 2 hours, 1 day, 7 days, and 21 days (after surgery)

Marker of systemic inflammation and soft tissue injury

Baseline, 2 hours, 1 day, 7 days, and 21 days (after surgery)
Creatine Kinase (CK)
Tidsramme: Baseline, 2 hours, 1 day, 7 days, and 21 days (after surgery)

Marker of systemic inflammation and soft tissue injury

Baseline, 2 hours, 1 day, 7 days, and 21 days (after surgery)
Duration of surgery in minutes
Tidsramme: Within the first week after surgery

The time from when the surgeon of record starts the procedure until he/she leaves the procedure.

This information will be collected from the patient's medical record.

Within the first week after surgery
Postoperative x-rays
Tidsramme: On day of surgery, or postoperative day 1, or postoperative day 2

Postoperative x-rays of the knee are performed routinely in order to evaluate whether implants are placed in accordance with recommendations.

On day of surgery, or postoperative day 1, or postoperative day 2
Knee pain (VAS)
Tidsramme: Day 1, day 7, day 21, 3 months, 6 months, 12 months, 24 months (after surgery)

Pain assessed using the visual analogue score (VAS) following surgery. The Scores go from 0-10. 0 = no pain. 10 = the most pain. The patients indicate how their pain during the last 24 hours fit in to the scale.

Day 1, day 7, day 21, 3 months, 6 months, 12 months, 24 months (after surgery)
Analgesia requirements after surgery
Tidsramme: Day 1, day 7, day 21, 3 months (after surgery)

Both preoperative and postoperative requirement of analgesia will be noted. Analgesia requirement will include Paracetamol, NSAID, Acetylic Acids and Opioids. Type of anaesthesia/sedation used during surgery will in addition be recorded. The above information will be collected from the patient's medical record.

Day 1, day 7, day 21, 3 months (after surgery)
Perioperative complications
Tidsramme: 1 day During admission (after surgery)

Complications which happens during surgery.

1 day During admission (after surgery)
Length of stay/ Re-admissions within the first 90 days
Tidsramme: 90 days (after surgery)

The patients are expected to be discharged on day 1 post-surgery after a blood sample is taken at 24 hours post-surgery. It will be recorded if a patient is not able to be discharged at this time and for how many days the admission will last. The number of readmissions within 90 days of surgery and the reason for re-admission will also be recorded. This information will be collected from the patient's medical journal.

90 days (after surgery)
90 days complications (medical, surgical)
Tidsramme: 90 days (after surgery)

Complications (both medical and surgical) arising within 90 days of surgery will be recorded. The information will be collected from the patient's medical records.

Complications includes myocardial infarction/cardiac events, cerebrovascular events, venous thromboembolism, deep infection, reoperation, revision, and death.

90 days (after surgery)
Data on any revisions performed on includes patient within 24 months
Tidsramme: 24 months (after surgery)

Any revisions in patients within 24 months will be recorded. The reason for revision and the type of revision will be noted. The information will be collected from the patient's medical records.

24 months (after surgery)
Pain Catastrophizing Scale (PCS)
Tidsramme: Baseline

The Pain Catastrophizing Scale (PCS) is a 13-item patient reported outcome measure developed to evaluate catastrophic thinking related to pain. Standardized answer options are given through a 5-point Likert scales, from 0 (not at all) to 4 (all the time). Higher scores indicate higher level of catastrophizing. A total score yielding (ranging from 0-52), along with three subscale scores assessing rumination, magnification, and helplessness.

Baseline
Pain Detect Questionnaire (PDQ)
Tidsramme: Baseline

The PDQ is a patient administered questionnaire used to assess the likelihood of a pain experience being of neuropathic origin.

Baseline
Oxford Knee Score (OKS)
Tidsramme: Baseline, 3 months, 6 months, 12 months, 24 months (after surgery)

The Oxford Knee Score (OKS) is a 12-item patient reported outcome questionnaire developed specifically to assess the patient's perspective on the outcomes of knee arthroplasty with respect to combined pain and physical function. Standardized answer options are given (5 Likert boxes) and each question is assigned a score from 0 to 4. Thus, a total score is calculated from 0 to 48, with 48 indication the best outcome. The OKS is short, practical, reliable, valid, and sensitive to clinically important changes over time18.

Baseline, 3 months, 6 months, 12 months, 24 months (after surgery)
The Forgotten Joint Score
Tidsramme: Baseline, 3 months, 6 months, 12 months, 24 months (after surgery)

The Forgotten Joint Score was designed to assess patient outcome in patients undergoing conservative or operative treatment of the knee, and it analyses patient's ability to forget about a joint as a result of successful treatment. The questionnaire consists of 12 questions that are equally weighted and measure patient satisfaction. Standardized answer options are given (6 Likert boxes). Scores are summed to create a composite score that is converted to a 100-point scale. Higher scores indicate greater satisfaction.

Baseline, 3 months, 6 months, 12 months, 24 months (after surgery)
European Quality of Life questionnaire with 5 dimensions for adults (EQ-5D)
Tidsramme: Baseline, 3 months, 6 months, 12 months, 24 months (after surgery)

EQ-5D-5L is a standardized patient-reported instrument for measurement of health outcome and quality of life. EQ-5D-5L is designed for self-completion by respondents and is ideally suited for use in surveys. The EQ-5D-5L consists of 2 pages - the EQ-5D-5L description system and the EQ Visual Analogue Scale (EQ VAS). The descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Standardized answer options are given (5 22.12.2022 Page 17 of 30 Likert boxes) and each question is assigned a score from 1 to 5. Instructions to respondents are included in the questionnaire. The EQ VAS records the respondent's self-rated health on a 20 visual analogue scale with endpoints labelled "the best health you can imagine" and "the worst health you can imagine". This information can be used as a quantitative measure of health judged by the individual respondents.

Baseline, 3 months, 6 months, 12 months, 24 months (after surgery)
Patient acceptable Symptom States (PASS)
Tidsramme: 3 months, 6 months, 12 months, 24 months (after surgery)

One question regarding PASS will be used to assess how many patients consider themselves well after surgery (as opposed to feeling better). PASS is assessed as a dichotomous outcome (yes/no) to the question:"Taking into account all the activities you have during your daily life, your level of pain, and also your functional impairment, do you consider that your current state is satisfactory?". The actual question asked will be in Danish (Appendix G).

3 months, 6 months, 12 months, 24 months (after surgery)
Treatment failure (TF)
Tidsramme: 3 months, 6 months, 12 months, 24 months (after surgery)

We will define treatment failure in two ways:

  1. Patients replying 'no' to the PASS question (above) will be asked to answer (yes/no) the following question: "Would you consider your current state as being so unsatisfactory that you think the treatment has failed?" Patients replying, 'yes' to this second question will be defined as experiencing 'treatment failure' (TF).
  2. Patients who during the observation period undergo revision surgery are defined as TF. We will seek information about the reason for revision surgery (e.g. infection, malalignment, loosening/lysis, implant wear, dislocation/instability, stiffness, pain, and other reasons) in the medical records.
3 months, 6 months, 12 months, 24 months (after surgery)

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Anders Troelsen, MD, PhD, DMSc, Department of Orthopaedic Surgery, Amager Hvidovre Hospital, Kettegård Alle 30, DK-2650 Hvidovre

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

20. februar 2023

Primær fullføring (Faktiske)

30. mars 2024

Studiet fullført (Faktiske)

28. februar 2026

Datoer for studieregistrering

Først innsendt

30. januar 2023

Først innsendt som oppfylte QC-kriteriene

17. februar 2023

Først lagt ut (Faktiske)

21. februar 2023

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

22. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

17. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

IPD-planbeskrivelse

No plan

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere